###### Key messages

What is the key question?
=========================

-   What is the distribution of bronchodilator response in healthy populations worldwide?

What is the bottom line?
========================

-   We have generated global population-based thresholds for bronchodilator reversibility testing.

Why read on?
============

-   The article provides new insights into global bronchodilator response and reversibility.

Introduction
============

Airway responsiveness to a bronchodilator is widely performed in most clinical respiratory function laboratories throughout the world. Bronchodilator response (BDR) is used to predict a patient\'s response to bronchodilator treatment, to establish best attainable lung function, and in clinical trials, to rule in or rule out asthma and chronic obstructive pulmonary disease (COPD).[@b1; @b2; @b3; @b4; @b5] Although much has been learned about BDR, there continues to be confusion about its clinical usefulness,[@b6] [@b7] its pathophysiological basis, its expression[@b8; @b9; @b10] and its determinants.[@b11]

There is also a lack of consensus on the criteria for a significant or increased BDR.[@b12] [@b13] One obstacle is the lack of agreement on how the response should be expressed.[@b8; @b9; @b10] [@b12] Another is paucity of normative reference data derived from healthy general populations, as has been recommended by the American Thoracic Society (ATS)[@b12] and the European Respiratory Society (ERS) guidelines.[@b13] The most common recommendation of a 'cut-off' of 12% change in FEV~1~ from baseline for significant bronchial responsiveness has been derived from patients with obstructive lung disease.[@b8] [@b9] [@b14; @b15; @b16; @b17] It is conceivable that these cut-offs may not reflect the spectrum of responsiveness in a healthy general population.[@b12] To date, the information derived from general populations is patchy,[@b18; @b19; @b20] and none comes from non-Western countries. A better understanding of the worldwide distribution of BDR in health and disease would be helpful for developing global criteria for BDR for clinical use and research.

In this paper we report the BDR in terms of changes in forced expiratory volume in 1 s (FEV~1~) and in forced vital capacity (FVC), measured in population-based samples from 14 country sites that participated in the Burden of Obstructive Lung Disease (BOLD) study.[@b21] [@b22] The focus in this descriptive report is the distribution of BDR in healthy populations, with comparison in subpopulations with chronic airway obstruction. From these, we generated the 95th percentiles and tested for variability and consistency across countries and within the pooled sample from all countries. This study, which drew participants from countries in North America, Europe, Africa, and Asia, provided the opportunity for a systematic evaluation of the reference range of airway response after bronchodilator in healthy general populations in different regions of the world.

Methods
=======

Subject design and participants
-------------------------------

The target population included women and men aged 40 years and older in random population samples from 14 countries in North America, Europe, Africa and Asia. A detailed description of the study design and rationale, and initial results of the BOLD study have been published elsewhere.[@b21] [@b22] Population-based sampling plans were used to recruit participants who were then invited to complete interviewer-administered standardised questionnaires on respiratory health and symptoms, smoking history, quality of life, use of healthcare services, cardiovascular comorbidities and other respiratory diseases. Pre-bronchodilator and post-bronchodilator spirometry testing was done for all eligible participants.

Spirometric testing and quality assurance review
------------------------------------------------

Lung function was obtained at all BOLD sites with the use of a portable spirometer (EasyOne, ndd Medical Technologies, Andover, Massachusetts, USA) to collect data on FEV~1~ and FVC with forced expiratory time standardised at \>6 s or a plateau in the last second of expiration. With the rare exception in which spirometry was contraindicated,[@b21] [@b22] all sites attempted to collect pre- and post-bronchodilator measurements from all participants. Lung function was measured before and 15 min after administering two doses of 100 μg of salbutamol (albuterol) via a spacer. All spirograms were reviewed by the BOLD Pulmonary Function Reading Center and assigned a quality score based on acceptability and repeatability criteria from the ATS.[@b23] Data for FEV~1~ and FVC were deemed usable and included in this analysis if they fully met ATS acceptability criteria and were repeatable to within 200 ml.

Definition of COPD
------------------

As in all BOLD publications, we used the Global Initiative for Chronic Obstructive Lung Disease (GOLD) post-bronchodilator lung function criteria for defining and staging COPD,[@b21] [@b24] and the prediction equations for Caucasian derived from the third US National Health and Nutrition Examination Survey[@b25] to compute percentage predicted FEV~1~ and FVC. COPD is defined as GOLD stage 2 and greater for subgroups computation.

Statistical analysis
--------------------

### Indices of BDR

We generated six measures of BDR, three each for FEV~1~ and FVC, using indices recommended by the ATS[@b12] and the ERS[@b10]: Absolute change from baseline values (ΔFEV~1~ and ΔFVC)[@b10]; [@b12] percentage change relative to initial value (%ΔFEV~1i~ and %ΔFVC~i~)[@b10] [@b12]; and percentage change relative to predicted value (%ΔFEV~1p~ and %ΔFVC~p~).[@b8] [@b9] [@b13] [@b18]

### Establishment of the upper normal limit of BDR

The 'normal' range of BDR was determined from its distribution among healthy never-smoking participants, defined as never smokers who did not report current asthma, chronic bronchitis, doctor diagnosis of emphysema, COPD or tuberculosis. The upper limit of normality of the BDR was defined as the observed upper 95th percentile[@b18] calculated separately for each site. These estimates and their associated 95% CIs were then used to generate forest plots and accompanying weighted estimates of the 95th percentiles that are pooled across sites along with tests for heterogeneity across sites. Individual sites are weighted according to the precision of the estimate at that site and these weights are reflected in the forest plots. We used simple unweighted statistics to summarise various statistics in tabular form for the cohort overall and for subgroups. All analyses were done using Stata V.10.0 (Stata Corp), and the forest plot analyses used the metan procedure.

Results
=======

Of a total of 10 712 subjects, 10 360 (97%) had either acceptable pre-bronchodilator and post-bronchodilator FEV~1~ data (n=10 217) or acceptable pre-bronchodilator and post-bronchodilator FVC data (n=9546) and are included in this analysis. [Table 1](#tbl1){ref-type="table"} shows their demographical and baseline characteristics by site. The mean ages and SDs ranged from 52.3 (10.3) years in the Philippines to 60.1 (12.8) years in Norway. Patterns of current cigarette smoking varied widely across sites: the lowest smoking rate was 14% in Canada; the highest smoking rate was 46% in South Africa. The intensity of tobacco exposure for smokers expressed as mean (SD) pack-years ranged from 17.0 (17.4) in South Africa to 38.6 (28.9) in Kentucky, USA.

###### 

Demographics and baseline characteristics of 10 360 participants with usable spirometry data

                                                     Australia     Austria       Canada        China         Germany       Iceland       Kentucky      Norway        Philippines   Poland        South Africa   Sweden        Turkey        UK
  -------------------------------------------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- -------------- ------------- ------------- -------------
  N                                                  558           1298          845           572           704           760           517           676           916           562           865            553           846           688
  Age (years)                                        59.0 (12.4)   57.7 (11.6)   56.1 (11.9)   54.0 (10.9)   58.2 (11.0)   56.4 (11.8)   56.7 (9.9)    60.1 (12.8)   52.3 (10.3)   55.8 (11.6)   54.2 (10.4)    58.4 (11.0)   53.7 (10.6)   58.2 (11.5)
  Current smoker, %                                  14.3          19.2          13.5          28.2          20.6          18.3          26.3          26.0          32.4          28.8          45.9           14.7          33.7          21.1
  Cigarette exposure                                                                                                                                                                                                                        
   Pack-years (full cohort)                          12.4 (25.4)   13.2 (20.9)   11.9 (23.4)   11.1 (17.9)   15.1 (20.9)   12.8 (24.9)   23.4 (29.3)   12.7 (16.5)   9.7 (17.1)    16.1 (25.3)   11.5 (16.3)    10.5 (16.2)   16.0 (27.0)   16.3 (31.8)
   Pack-years (ever smokers)                         24.6 (31.3)   25.3 (23.1)   22.7 (29.1)   26.8 (18.8)   25.1 (21.9)   21.0 (29.1)   38.6 (28.9)   20.1 (16.7)   18.5 (19.8)   26.3 (28.0)   17.0 (17.4)    18.3 (17.7)   29.6 (30.8)   26.3 (36.9)
  BMI (kg/m^2^)                                      28.0 (5.1)    26.4 (4.2)    26.7 (5.2)    23.2 (3.4)    27.3 (4.6)    27.9 (4.9)    30.7 (6.9)    26.5 (4.3)    24.8 (4.7)    27.6 (4.7)    27.8 (7.4)     27.0 (4.4)    29.5 (5.5)    27.1 (5.0)
  Pre-BD FEV~1~, % pred                              93.3 (18.1)   92.8 (17.5)   95.6 (18.4)   84.8 (14.8)   95.2 (17.5)   89.8 (16.4)   83.4 (18.8)   92.3 (16.7)   74.7 (15.4)   92.2 (18.3)   76.8 (19.5)    93.0 (16.1)   89.0 (18.5)   87.6 (17.9)
  Post-BD FEV~1~, % pred                             95.9 (17.3)   95.5 (16.7)   99.2 (17.9)   86.5 (14.5)   97.5 (16.9)   93.0 (16.0)   86.7 (18.2)   94.7 (16.5)   77.0 (15.1)   94.9 (17.8)   79.4 (19.0)    95.8 (16.1)   92.3 (17.7)   90.7 (17.3)
  GOLD stages[\*](#table-fn1){ref-type="table-fn"}                                                                                                                                                                                          
   Stage 1, %                                        8.3           14.8          10.2          4.3           8.1           8.6           5.4           11.9          1.2           11.6          4.0            9.6           8.6           11.0
   Stage 2, %                                        9.3           8.3           6.3           5.6           5.6           6.7           10.7          7.7           7.1           8.6           13.0           4.7           9.1           9.3
   Stage 3, %                                        1.3           1.1           0.7           1.5           0.7           1.6           3.7           0.9           3.7           1.8           5.8            1.5           1.1           2.1
   Stage 4, %                                        0.0           0.1           0.2           0.2           0.2           0.3           0.2           0.5           0.7           0.0           0.6            0.0           0.4           0.2
  Any respiratory medication, %                      23.0          6.4           32.4          2.6           19.7          30.0          44.0          13.8          26.5          8.6           9.8            41.6          6.0           22.5
  Asthma ever, %                                     17.2          7.1           14.3          3.2           9.7           16.7          22.1          17.3          6.6           7.3           14.7           14.5          6.4           19.5

Continuous data presented as mean (SD) unless otherwise stated.

GOLD stage I: FEV~1~/FVC\<70% and FEV~1~≥80% predicted; GOLD stage II: FEV~1~/FVC\<70% and 50%≤FEV~1~\<80% predicted; GOLD stage III: FEV~1~/FVC\<70% and 30%≤FEV~1~\<50% predicted; GOLD stage IV: FEV~1~/FVC\<70% and FEV~1~\<30% predicted.

BMI, body mass index; FEV~1~, forced expiratory volume in 1 s; GOLD, Global Initiative for Chronic Obstructive Lung Disease; FVC, forced vital capacity; Pre-BD FEV~1~ % pred, pre-bronchodilator FEV~1~ % predicted; Post-BD FEV~1~ % pred, post-bronchodilator FEV~1~ % predicted.

All indices of BDR in FEV~1~ and FVC displayed normal or near-normal distribution for the whole study population. [Table 2](#tbl2){ref-type="table"} shows the simple unweighted estimates of the mean change and SD of BDR. For the healthy subgroup, these averages were several fold smaller than the mean values for the subgroup with COPD. [Table 3](#tbl3){ref-type="table"} shows the simple unweighted estimates of the upper 95th percentiles (and associated 95% CIs) for the whole study population and for selected subgroups. BDR, when expressed as an absolute change, was larger in men than in women. However the opposite pattern was seen when BDR was expressed as a percentage change. In addition, per cent change when expressed relative to initial value was always greater (sometimes markedly so) when expressed relative to initial rather than predicted value. Finally, the 95th percentiles were consistently larger for individuals with COPD (regardless of comorbid asthma status) than for healthy lifetime never smokers.

###### 

Mean and SD (unweighted values) for bronchodilator responses for whole study population, healthy and COPD subgroups

  Variables               Study population   Healthy subgroup   COPD GS2+   COPD GS2+ (without asthma)                
  ----------------------- ------------------ ------------------ ----------- ---------------------------- ------------ ------------
  FEV~1~-based measures   N1=10 217          N1=4826            N1=5391     N1=3922                      N1=1009      N1=745
   ΔFEV~1~ (ml)           82 (139)           95 (156)           70 (120)    72 (130)                     114 (157)    104 (153)
   ΔFEV~1i~ (%)           3.7 (6.9)          3.6 (6.5)          3.8 (7.3)   3.1 (6.0)                    8.8 (11.9)   7.7 (11.0)
   ΔFEV~1p~ (%)           2.8 (4.8)          2.7 (4.6)          2.8 (5.0)   2.6 (4.8)                    4.2 (5.7)    3.7 (5.5)
                                                                                                                      
  FVC-based measures      N2=9546            N2=4560            N2=4986     N2=3593                      N2=976       N2=723
   ΔFVC (ml)              0 (237)            4 (257)            −4 (217)    −21 (219)                    153 (280)    138 (273)
   ΔFVC~i~ (%)            0.5 (7.9)          0.5 (6.9)          0.5 (8.7)   −0.3 (7.4)                   6.9 (12.2)   6.2 (11.9)
   ΔFVC~p~ (%)            0.1 (6.6)          0.2 (5.9)          0 (7.3)     −0.5 (6.7)                   4.4 (7.9)    4.0 (7.6)

ΔFEV~1~ (ml) and ΔFVC (ml) are absolute change after bronchodilator; ΔFEV~1i~ and ΔFVC~i~ are change as a per cent of initial value.

ΔFEV~1p~ and ΔFVC~p~ are change as per cent of predicted value. N1 is number with non-missing FEV~1~ values and N2 is number with non-missing FVC values.

COPD GS2+ = FEV~1~/FVC \<0.7 and FEV~1~% predicted\<80%; COPD GS2+ (without asthma) = post-bronchodilator spirometrically defined COPD excluding those with self-reported asthma.

COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in 1 s; FVC, forced vital capacity.

###### 

Upper 95th percentiles with 95% CI (unweighted values) for bronchodilator responses for whole study population, healthy and COPD subgroups

  Variables               Study population      Healthy Subgroup      COPD GS2+             COPD GS2+ (without asthma)                         
  ----------------------- --------------------- --------------------- --------------------- ---------------------------- --------------------- ---------------------
  FEV~1~-based measures   N1=10 217             N1=4826               N1=5391               N1=3922                      N1=1009               N1=745
   ΔFEV~1~ (ml)           314 (306 to 324)      354 (340 to 368)      265 (257 to 278)      291 (279 to 309)             371 (343 to 402)      341 (323 to 381)
   ΔFEV~1i~ (%)           14.6 (14.1 to 15.3)   14.0 (13.2 to 14.6)   15.4 (14.5 to 16.0)   12.5 (11.9 to 13.2)          30.9 (27.8 to 33.8)   27.7 (21.6 to 30.9)
   ΔFEV~1p~ (%)           10.6 (10.3 to 10.9)   10.2 (9.9 to 10.6)    10.9 (10.5 to 11.3)   10.1 (9.7 to 10.7)           13.1 (12.3 to 14.6)   12.3 (11.6 to 13.5)
                                                                                                                                               
  FVC-based measures      N2=9546               N2=4560               N2=4986               N2=3593                      N2=976                N2=723
   ΔFVC (ml)              395 (381 to 414)      454 (419 to 486)      347 (328 to 374)      337 (317 to 358)             635 (591 to 678)      619 (547 to 668)
   ΔFVC~i~ (%)            13.3 (12.7 to 13.9)   12.6 (11.8 to 13.4)   14.1 (13.2 to 15.1)   11.2 (10.5 to 12.2)          29.4 (26.6 to 31.6)   26.7 (24.4 to 30.6)
   ΔFVC~p~ (%)            10.8 (10.4 to 11.4)   10.4 (9.7 to 10.8)    11.6 (10.7 to 12.5)   9.6 (9.1 to 10.3)            18.0 (17.0 to 19.7)   17.3 (15.7 to 18.8)

ΔFEV~1~ (ml) and ΔFVC (ml) are absolute change after bronchodilator; ΔFEV~1i~ and ΔFVC~i~ are change as a per cent of initial value; ΔFEV~1p~ and ΔFVC~p~ are change as per cent of predicted value. N1 is number with non-missing FEV~1~ values and N2 is number with non-missing FVC values.

COPD GS2+ = FEV~1~/FVC \<0.7 and FEV~1~% predicted\<80%; COPD GS2+, without asthma = COPD GS2+ but with no self-reported diagnosis of asthma.

In the COPD subgroups, the CIs for individual sites were large due to small sample size (\<50).

COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in 1 s; FVC, forced vital capacity.

[Figures 1--6](#fig1 fig2 fig3 fig4 fig5 fig6){ref-type="fig"} show the forest plots of the upper 95th percentile for the six measures of BDR for the subset of healthy never smokers. More precise estimates received greater weight, as shown in the figures, when calculating the pooled estimates, and hence the pooled estimates here differ somewhat from the unweighted estimates of 95th percentiles for all subjects shown in [table 3](#tbl3){ref-type="table"}, although they are qualitatively similar. In healthy lifetime non-smokers, the pooled weighted estimate of the threshold for absolute change (ΔFEV~1~) is 284 ml, with significant cross-site heterogeneity in estimates, that is 54% of overall variation in estimate comes from site to site variability ([figure 1](#fig1){ref-type="fig"}). The pooled weighted estimate for %ΔFEV~1p~ ([figure 3](#fig3){ref-type="fig"}) is smaller than for %ΔFEV~1i~ ([figure 2](#fig2){ref-type="fig"}), with no cross-site heterogeneity in both cases. In contrast, the estimates for the FVC-based thresholds ([figures 4--6](#fig4 fig5 fig6){ref-type="fig"}) all demonstrated marked cross-site heterogeneity, ranging from 66% to 80%.

![Absolute change in forced expiratory volume in 1 s (FEV~1~) in ml after bronchodilator (ΔFEV~1~) expressed as 95th percentile with 95% CI in healthy non-smokers. Those sites whose estimates are most stable get greater weight (right-hand column) in constructing the pooled estimate of 284 ml. We observed significant heterogeneity across sites (p=0.008), with 54% of the overall variability in the data attributable to site--site variability.](thoraxjnl-2011-201445fig1){#fig1}

![Percentage change in forced expiratory volume in 1 s (FEV~1~) relative to initial baseline, after bronchodilator (BDR FEV~1i~) expressed as 95th percentile with 95% CI in healthy non-smokers. The pooled estimate is 12% with no evidence of cross-site heterogeneity.](thoraxjnl-2011-201445fig2){#fig2}

![Percentage change in forced expiratory volume in 1 s (FEV~1~) relative to predicted FEV~1~, after bronchodilator (%ΔFEV~1p~) expressed as 95th percentile with 95% CI in healthy non-smokers. The pooled estimate is 10% with no evidence of cross-site heterogeneity.](thoraxjnl-2011-201445fig3){#fig3}

![Absolute change in forced vital capacity (FVC) after bronchodilator (BDR FVC, ml) expressed as 95th percentile with 95% CI in healthy non-smokers. Those sites whose estimates are most stable get greater weight (right-hand column) in constructing the pooled estimate of 322 ml. We observed significant heterogeneity across sites (p\<0.0001), with 75% of the overall variability in the data attributable to site--site variability.](thoraxjnl-2011-201445fig4){#fig4}

![Percentage change in forced vital capacity (FVC) relative to initial baseline, after bronchodilator (BDR FVC~1i~) expressed as 95th percentile with 95% CI in healthy non-smokers. Those sites whose estimates are most stable get greater weight (right-hand column) in constructing the pooled estimate of 11%. We observed significant heterogeneity across sites (p\<0.0001), with 66% of the overall variability in the data attributable to site--site variability.](thoraxjnl-2011-201445fig5){#fig5}

![Percentage change in forced vital capacity (FVC) relative to predicted FVC, after bronchodilator (BDR FVC~p~) expressed as 95th percentile with 95% CI in healthy non-smokers. Those sites whose estimates are most stable get greater weight (right-hand column) in constructing the pooled estimate of 9%. We observed significant heterogeneity across sites (p\<0.0001), with 80% of the overall variability in the data attributable to site--site variability.](thoraxjnl-2011-201445fig6){#fig6}

Using the weighted thresholds from [figures 1--6](#fig1 fig2 fig3 fig4 fig5 fig6){ref-type="fig"}, we then calculated the simple, unweighted proportion of individuals who exceeded these thresholds for various subgroups ([table 4](#tbl4){ref-type="table"}). The proportion of people without airway obstruction who exceeded the threshold was consistently lower than that for people with airway obstruction for both the FEV~1~-based and FVC-based thresholds. The proportion of people in the COPD subgroups who exceeded the FEV~1~-based thresholds (except for ΔFEV~1i~) decreased with increasing severity of COPD as defined by GOLD stages.[@b24] By contrast, the proportion of people in the COPD subgroups who exceeded the FVC-based thresholds showed a tendency to increase with severity.

###### 

The proportion of people in excess of thresholds for overall cohort, for subgroups of normal, GOLD stage 1, GOLD stage 2 and GOLD stage 3--4

  Variables                 Overall     Normal    GOLD stage 1   GOLD stage 2   GOLD stage 3--4
  ------------------------- ----------- --------- -------------- -------------- -----------------
  FEV~1~-based thresholds   N1=10 217   N1=7931   N1=846         N1=790         N1=219
   ΔFEV~1~ (\>284 ml)       6.7%        5.6%      11.5%          12.2%          7.3%
   ΔFEV~1i~ (\>12%)         7.8%        4.4%      11.6%          27.3%          43.4%
   ΔFEV~1p~ (\>10%)         6.0%        4.3%      12.3%          13.9%          9.1%
                                                                                
  FVC-based thresholds      N2=9546     N2=7697   N2=819         N2=764         N2=212
   ΔFVC (\>322 ml)          7.5%        4.0%      21.2%          20.7%          29.7%
   ΔFVC~i~ (\>10.5%)        7.5%        3.8%      17.0%          24.7%          42.5%
   ΔFVC~p~ (\>9.2%)         6.8%        3.2%      21.6%          20.5%          27.8%

ΔFEV~1~ (ml) and ΔFVC (ml) are absolute change after bronchodilator; ΔFEV~1i~ and ΔFVC~i~ are change as a per cent of initial value; ΔFEV~1p~ and ΔFVC~p~ are change as per cent of predicted value. N1 is number with non-missing FEV~1~ values and N2 is number with non-missing FVC values.

Normal = not classified as any GOLD stage; GOLD stage 1 = FEV~1~/FVC \<0.7 and FEV~1~ % predicted \>80%; GOLD stage 2 = FEV~1~/FVC \<0.7 and FEV~1~ % predicted \<80% and \>50%; GOLD stage 3--4 = FEV~1~/FVC \<0.7 and FEV~1~ % predicted \<50%.

COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in 1 s; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease.

Discussion
==========

We measured the BDR in general population samples, aged 40 and older, from sites in 14 countries spanning four continents. The main findings indicated that the thresholds or upper limit of normality for the per cent change in FEV~1~ relative to initial level is 12% and for the FEV~1~ relative to predicted FEV~1~ is 10% without heterogeneity across populations. These values agree well with current ATS guideline cutoffs for defining a significant BDR and strengthen the applicability of these measures for global interpretation in bronchodilator testing. We further validated these thresholds in people with and without obstruction and confirmed that a higher proportion of people with obstruction of all stages of severity had BDR compared with those without obstruction, findings that are consistent with previous studies in healthy individuals and people with airway obstruction using ATS-ERS thresholds.[@b10]

There were two secondary findings. First, the BDR threshold for people with chronic airflow obstruction was lower when asthma was excluded, but there was considerable overlap between the two groups with and without exclusion of asthma, consistent with previous studies.[@b1] [@b26] [@b27] Also, there were differences between the FEV~1~-based and the FVC-based thresholds in their association with severity of airflow obstruction. The proportion with reversibility measured by changes in FEV~1~ generally decreased as COPD severity increased while that with reversibility measured by changes in FVC increased with increasing COPD severity, findings which are consistent with the findings reported in clinical trials of patients with COPD, using ATS reversibility criteria.[@b4] These findings support the use of lung volume-based measures of reversibility in addition to FEV~1~-based measures in patients with more severe COPD.[@b26]

In this analysis the thresholds for BDR for healthy people were derived from random samples of adults aged 40 years and over in the general population. According to the ERS guidelines, an ambiguous BDR should exceed spontaneous variability and the response observed in healthy individuals.[@b13] Yet, evidence for the different published criteria had largely been based on data of selected patients with airflow limitation.[@b8] [@b9] [@b14; @b15; @b16; @b17] [@b28] Existing data on the upper limit of the BDR in the healthy population are few and dated,[@b18] [@b29] although a recent study of unselected urban population in Iceland reported a 95th percentile of 9% for increase in FEV~1~ from baseline (%ΔFEV~1i~).[@b19] Therefore, the results from this study add to reference values from smaller population studies from single countries[@b18; @b19; @b20] and provided global reference values for the interpretation of bronchodilator testing.

Two separate approaches have been used to derive reference values for a BDR. The first method was to assume that values greater than the 95th percentile in distribution of healthy subjects was abnormal.[@b18] The second method was to measure the short-term spontaneous variation or placebo-induced changes in FEV~1~ in patients.[@b15; @b16; @b17] The first method was used in this study. The joint ATS-ERS guidelines[@b10] recommendation of 12% percentage change from baseline and 200 ml absolute changes in FEV~1~ and/or FVC in an individual subject to identify a positive/significant BDR was derived using the second approach, but recognised the need to obtain references in healthy populations based on the first method. Thus, the results from this study provided new data relevant to this gap in information.

The 'cutoff' values in our analysis differ somewhat compared with those from single site population studies of healthy subjects. For defining a positive response, these studies had suggested 95th percentile thresholds of 130 ml[@b18] or 240 ml[@b19] for absolute change in FEV~1~; 9%[@b18] or 5.9%[@b19] for percentage change in FEV~1~ from initial value (%∆FEV~1i~) and 9%[@b8] [@b18] for change in FEV~1~ relative to predicted value (%∆FEV~1p~). In our study, the derived cutoffs for %∆FEV~1i~ and %∆FEV~1p~ are higher but stable as evidenced by the lack of site heterogeneity. Also, these threshold values complied with the caution to exceed the measurement variability of at least 8% change within individuals for defining an unambiguous response.[@b8] [@b30] [@b31] The FVC thresholds were included as the ATS-ERS recommendation included these[@b10] to accommodate flow responders and volume responders to inhaled bronchodilators.[@b32] [@b33] However, it is worth noting that the issue of heterogeneity is much more a concern for FVC than for FEV~1~, at least so long as the latter is expressed as a per cent change of initial or predicted value.

Comparison of our healthy population-based thresholds with the thresholds of guidelines based on patient studies provided insight into the short-term variability of BDR measurements. In this global study, the 95th percentile cutoffs of BDR in healthy never smokers of 12% for ΔFEV~1i~ was identical to the cutoffs of 12% change in FEV~1~ or FVC for a positive response required by international guidelines,[@b10] while 10% for ΔFEV~1p~ was similar to the 9% change found by one study.[@b8] The guideline recommendation for a positive BDR had been based on observations in selected patients with asthma and COPD, and on the fact that there was a short-term intra-subject variability of 200 ml in flow volume indices.[@b34] Although the long-term variability in lung function in patients is larger than in healthy subjects, the short-term variability in patients in a stable condition is very similar to normal subjects, with an observed 95% CI of change in FEV~1~ of 190 ml and 12.3%.[@b15] [@b16] This could be a potential explanation for the similarity between threshold values in our study and the guideline recommendations.[@b10]

There is no consensus on how BDR is best expressed: in absolute terms or as percentage of the initial value,[@b10] [@b12] or as percentage of predicted value.[@b13] Of the six indices of BDR in this global study, we showed that the percentage change in FEV~1~ relative to either baseline or predicted were the most stable across sites, while there was significant site-to-site variability in all FVC estimates and in absolute FEV~1~ change. Overall, this population-based evidence supports the use of 10% increase relative to predicted FEV~1~ to determine bronchodilator reversibility, as this feature is stable across sites, is independent of sex and stable across GOLD stages, yet discriminates healthy subjects from obstructive individuals. Nevertheless, in practice, it would be prudent to couple any percentage threshold with a qualifying volume threshold.[@b10]

This is the first study to compare BDR in population-based samples from a large number of sites on several continents. This information adds to the growing body of data on lung function that will help us to understand the range of normality and what may influence this. Other strengths of the study include the careful attention to standardisation and quality control used across all sites in the BOLD study[@b21] [@b22] and the well recognised technique of defining the 95th percentile in the healthy population for deriving the reference for BDR thresholds.[@b18] [@b19] In addition, the analysis of FVC data using different criteria is much more comprehensive than in other reports.[@b6]

A potential limitation of the study is that our definition of healthy never smokers relies on self-report of doctor-diagnosed lung disorders rather than objectively defined obstructive lung disease, since both diagnostic practices and access to care might vary across our widely dispersed sites. Nonetheless this is standard practice for developing reference equations for lung function.[@b25] Also, we would note that only 4% of our healthy never smokers met criteria for GOLD stage 2 or higher COPD, suggesting that the results would be unlikely to change much by excluding these individuals, and indeed we confirmed this for [tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"} (data not shown). Second, because the distribution of BDRs are continuous and unimodal as had been shown in clinical studies[@b8] [@b9] [@b15] and population studies,[@b18; @b19; @b20] the cutoff value for a 'positive' response in all studies, including ours, remained somewhat arbitrary.[@b35] Third, we used 200 μg of salbutamol/albuterol instead of higher doses as an extra precaution because it was a field study and involved home visits in many sites. While GOLD guidelines recommended 400 μg, many published clinical studies have used different types and doses of drugs as summarised in the recent paper on bronchodilator reversibility by Hanania *et al*.[@b26] Lastly, we demonstrated the effect of acute reversibility due to bronchodilator in one setting but not its reproducibility on repeated testing and also not the long-term reversibility due to anti-inflammatory drugs. Hence, a lack of a response to bronchodilator testing in one setting may not preclude a clinical response to bronchodilating or anti-inflammatory therapy.[@b10] [@b24]

In conclusion, the results from this study add new worldwide data on the distribution of bronchodilator response and airway reversibility. The reference values derived from healthy individuals addressed the reference gap in BDR. The values agreed well with the current guideline cutoffs for a significant BDR, were discriminative for different subpopulations and strengthen the applicability of these measures for global interpretation in bronchodilator testing.
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